Randomised trial comparing as-needed versus regular treatment with formoterol in patients with persistent asthma

Respiratory Medicine

Volumn 101, Issue 3, 2007, Pages 467-475

  Richter, K ^a   Hartmann, U ^b   Metzenauer, P ^b   Magnussen, H ^a  

^a KRANKENHAUS GROSSHANSDORF   (Germany)

^b Astellas Pharma GmbH (formerly Fujisawa Deutschland GmbH)   (Germany)

Author keywords

As needed therapy; Asthma exacerbation; Drug consumption; Formoterol; Randomised trial

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDECORT 200; BUDESONIDE; FORMOTEROL; GLUCOCORTICOID; LACTOSE; SALBUTAMOL; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD PRESSURE; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CONTROL; DISEASE EXACERBATION; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; FEMALE; HUMAN; MALE; MAXIMUM PERMISSIBLE DOSE; MILD PERSISTENT ASTHMA; MODERATE PERSISTENT ASTHMA; MONOTHERAPY; MULTICENTER STUDY; MUSCULOSKELETAL PAIN; OPEN STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; PULSE RATE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT DURATION; TREMOR;

ADMINISTRATION, INHALATION; ADULT; ALBUTEROL; ASTHMA; BRONCHODILATOR AGENTS; DRUG ADMINISTRATION SCHEDULE; ETHANOLAMINES; FEMALE; HUMANS; MALE; PATIENT COMPLIANCE; SPIROMETRY; TIME FACTORS; TREATMENT OUTCOME;

EID: 33846666942     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2006.07.004     Document Type: Article

References (19)

1. McFadden Jr. E.R. Asthma. Harrison's principles of internal medicine. 15th ed (2001), McGraw-Hill, New York [Chapter 252]
2. GINA-Global Initiative for Asthma. Global strategy for asthma management and prevention. National Institutes of Health. National Heart, Lung and Blood Institute. GINA Workshop Report (Updated 2004). 〈www.ginasthma.com〉.
3. Wettengel R., Berdel D., Hofmann D., et al. Empfehlungen zur Asthmatherapie bei Kindern und Erwachsenen. Pneumologie 52 (1998) 591-601
4. Price D., Dutchman D., Mawson A., Bodalia B., Duggan S., and Todd P. Early asthma control and maintenance with eformoterol following reduction of inhaled corticosteroid dose. Thorax 57 (2002) 791-798
5. Zetterström O., Buhl R., Mellem H., et al. Improved asthma control with budesonide/formoterol in a single inhaler, compared with budesonide alone. Eur Respir J 18 (2001) 262-268
6. Pauwels R.A., Löfdahl C.G., Postma D.S., et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med 337 20 (1997) 1405-1411
7. Greening A.P., Ind P.W., Northfield M., and Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study. Lancet 344 (1994) 219-224
8. Woolcock A., Lundback B., Ringdal N., and Jacques L.A. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med 153 (1996) 1481-1488
9. Li X., Ward C., Thien F., et al. An antiinflammatory effect of salmeterol, a long-acting beta(2) agonist, assessed in airway biopies and bronchoalveolar lavage in asthma. Am J Respir Crit Care Med 160 (1999) 1493-1499
10. Richter K., Janicki S., Jörres R.A., and Magnussen H. Acute protection against exercise-induced bronchoconstriction by formoterol, salmeterol and terbutaline. Eur Respir J 19 (2002) 865-871
11. Faulds D., Hollingshead L.M., and Goa K.L. Formoterol. A review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease. Drugs 42 (1991) 115-137
12. Hoffman B.B. Catecholamines, sympathomimetic drugs, and adrenergic receptor antagonists. In: Goodman, and Gilman's (Eds). The pharmacological basis of therapeutics. 10th ed (2001), McGraw-Hill, New York 230-231 [Chapter 10]
13. Tattersfield A.E., Löfdahl C- G., Postma D.S., et al. Comparison of formoterol and terbutaline for as-needed treatment of asthma: a randomised trial. Lancet 357 (2001) 257-261
14. Boonsawat W., Charoenratanakul S., Pothirat C., et al. Formoterol (OXIS) Turbuhaler as a rescue therapy compared with salbutamol pMDI plus spacer in patients with acute severe asthma. Respir Med 97 9 (2003) 1067-1074
15. Richter K., Metzenauer P., Ellers-Lenz B., Maus J., Petzold U., and Magnussen H. Bronchodilator effect of formoterol delivered by two different dry powder inhalers (DPI). Eur Respir J 24 48 (2004) [Abstract 310 s, Poster P1985]
16. Quanjer Ph.H., Tammeling G.J., Cotes J.E., Pedersen O.F., Peslin R., and Yernault J.C. Lung volumes and forced ventilatory flows. Eur Respir J 6 Suppl 16 (1993) 5-40
17. Pauwels R.A., Sears M.R., Campbell M., et al. Formoterol as relief medication in asthma: a worldwide safety and effectiveness trial. Eur Respir J 22 (2003) 787-794
18. Buhl R., Berdel D., Criée C.P., et al. Leitlinie zur Diagnostik und Therapie von Patienten mit Asthma. Pneumologie 60 (2006) 139-183
19. Martinez F.D. Safety of long-acting beta-agonists-an urgent need to clear the air. N Engl J Med 353 25 (2005) 2637-2639